Stemcell technologies INC:1109892 [23-003727] 01-easysep human pan-B cell enrichment kit OTS kit (quote: Q-450874) 02-CUS HU isolation kit one step custom CD86 and HLA-DR antibodies for kit #19666 -…
Ended Awarded Last action
- Contract number
- 75N92B23F90033
- Awardee
-
Stemcell Technologies Inc. UEI ELPMWCGFK518
- Awarding agency
-
National Insititue of Arthritis and Musculoskeletal and Skin Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $11,943
Award facts
- Contract value 100% obligated
- $11,943.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541380 Testing Laboratories and Services
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Burien, WA 98168, USA
Award details come from SAM.gov/FPDS.
About this award
STEMCELL Technologies Inc., a subsidiary of the Canadian parent company STEMCELL Technologies, received a $11,943 firm fixed-price contract award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) on June 8, 2022. This was a Blanket Purchase Agreement (BPA) call representing a repeat order for specialized cell isolation and enrichment products, specifically an EasySep Human Pan-B Cell Enrichment Kit and custom human isolation kit components featuring CD86 and HLA-DR antibodies. The contract was performed in Seattle, Washington, with an ultimate completion date of September 30, 2023. No small business set-aside was applied to this award.
This procurement falls under STEMCELL Technologies Inc.'s broader $10 million single-award Blanket Purchase Agreement with the National Institutes of Health Office of Logistics and Acquisition Operations, which runs through December 31, 2025, and facilitates streamlined acquisition of specialized biological materials and research reagents across multiple NIH institutes. The company serves as a critical supplier of cell isolation kits, cell culture media, and laboratory equipment supporting biomedical research in immunology, infectious diseases, and stem cell research. As a foreign-owned subsidiary, STEMCELL Technologies Inc. has demonstrated capacity to fulfill federal research needs directly, with contract values historically ranging from approximately $10,000 to $100,000 across various NIH institutes and centers.
Description
Stemcell technologies INC:1109892 [23-003727] 01-easysep human pan-B cell enrichment kit OTS kit (quote: Q-450874) 02-CUS HU isolation kit one step custom CD86 and HLA-DR antibodies for kit #19666 - repeat order from SAP so 0010396009 03-CUS HU is
Quick answers
Who was awarded contract 75N92B23F90033?
75N92B23F90033 was awarded to Stemcell Technologies Inc. by National Insititue of Arthritis and Musculoskeletal and Skin Diseases (National Institutes of Health) on June 8, 2022.
How much is contract 75N92B23F90033 worth?
The government has obligated $11,943 on 75N92B23F90033.
Is contract 75N92B23F90033 an order under another contract?
Yes. 75N92B23F90033 is a BPA call under HHSN263201500148B, a blanket purchase agreement.
Was contract 75N92B23F90033 competed?
The extent of competition for 75N92B23F90033 was competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award